Prostate cancer is the second most common malignancy among men in the world, posing a serious threat to men's health and lives. RB1 is the first human tumor suppressor gene to be described, and it is closely associated with the development, progression, and suppression of a variety of tumors. It was found that the loss of RB1 is an early event in prostate cancer development and is closely related to prostate cancer development, progression and treatment resistance. This paper reviews the current status of research on the relationship between RB1 and prostate cancer from three aspects: RB1 and prostate cell lineage plasticity; biological behavior; and therapeutic resistance. Providing a novel perspective for developing new therapeutic strategies for RB1-loss prostate cancer.
SungHFerlayJSiegelRL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin2021; 71: 209-249.
2.
GalliLChiuriVEDi LorenzoG, et al. First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry. Tumori2023; 109: 224-232.
3.
FuocoVArgiroffiGMazzagliaS, et al. Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori2022; 108: 315-325.
4.
AttardGParkerCEelesRA, et al. Prostate cancer. Lancet2016; 387: 70-82.
HarrisWPMostaghelEANelsonPS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol2009; 6: 76-85.
7.
ChenRDongXGleaveM. Molecular model for neuroendocrine prostate cancer progression. BJU Int2018; 122: 560-570.
8.
KanayamaMLuoJ. Delineating the molecular events underlying development of prostate cancer variants with neuroendocrine/small cell carcinoma characteristics. Int J Mol Sci2021; 22: 12742.
9.
SandhuSMooreCMChiongE, et al. Prostate cancer. Lancet2021; 398: 1075-1090.
10.
AhmedMEelesR. Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA2016; 2: FSO87.
11.
AhmadiyehNPomerantzMMGrisanzioC, et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A2010; 107: 9742-9746.
12.
RobinsonDVan AllenEMWuY-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell2015; 162: 454.
13.
Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell2015; 163: 1011-1025.
14.
StellatoMGuadalupiVSepeP, et al. The emerging role of PARP inhibitors in prostate cancer. Expert Rev Anticancer Ther2020; 20: 715-726.
15.
BerryJLPolskiACaveneeWK, et al. The story: Characterization and cloning of the first tumor suppressor gene. Genes2019; 10: 879.
16.
DannenbergJ-Hte RieleHPJ. The retinoblastoma gene family in cell cycle regulation and suppression of tumorigenesis. Results Probl Cell Differ2006; 42: 183-225.
17.
BurkeJRDeshongAJPeltonJG, et al. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem2010; 285: 16286-16293.
18.
ZhouLNgDS-CYamJC, et al. Post-translational modifications on the retinoblastoma protein. J Biomed Sci2022; 29: 33.
19.
RileyDJLiuCYLeeWH. Mutations of N-terminal regions render the retinoblastoma protein insufficient for functions in development and tumor suppression. Mol Cell Biol1997; 17: 7342-7352.
20.
TokiHInoueMMinowaO, et al. Novel retinoblastoma mutation abrogating the interaction to E2F2/3, but not E2F1, led to selective suppression of thyroid tumors. Cancer Sci2014; 105: 1360-1368.
21.
RubinSMGallA-LZhengN, et al. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell2005; 123: 1093-1106.
22.
CobrinikDDowdySFHindsPW, et al. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci1992; 17: 312-315.
23.
WeinbergRA. The retinoblastoma protein and cell cycle control. Cell1995; 81: 323-330.
24.
PardeeAB. G1 events and regulation of cell proliferation. Science1989; 246: 603-608.
25.
IndovinaPPentimalliFCasiniN, et al. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget2015; 6: 17873-17890.
26.
LinnPKohnoSShengJ, et al. Targeting RB1 Loss in Cancers. Cancers (Basel)2021; 13: 3737.
27.
KnudsonAGMeadowsATNicholsWW, et al. Chromosomal deletion and retinoblastoma. New Eng J Med1976; 295: 1120-1123.
28.
KnightLAGardnerHAGallieBL. Segregation of chromosome 13 in retinoblastoma. Lancet1978; 1: 989.
29.
ZoumpoulidouGAlvarez-MendozaCMancusiC, et al. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Comm2021; 12: 7064.
30.
NegriGLGrandeBMDelaidelliA, et al. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. J Pathol2019; 249: 319-331.
31.
PinyolMBeaSPlàL, et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood2007; 109: 5422-5429.
32.
RubioCMartínez-FernándezMSegoviaC, et al. CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of Status. Clin Cancer Res2019; 25: 390-402.
33.
RobertsonAGKimJAl-AhmadieH, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell2017; 171.
34.
JonesRARobinsonTJLiuJC, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest2016; 126: 3739-3757.
35.
WitkiewiczAKKnudsenES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. BCR2014; 16: 207.
36.
MeuwissenRLinnSCLinnoilaRI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell2003; 4: 181-189.
37.
DowlatiALipkaMBMcCollK, et al. Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol2016; 27: 642-647.
38.
OffinMChanJMTenetM, et al. Concurrent RB1 and TP53 alterations define a subset of egfr-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thoracic Oncol2019; 14: 1784-1793.
39.
ThomsonDWShahrinNHWangPPS, et al. Aberrant RAG-mediated recombination contributes to multiple str-uctural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia2020; 34: 2051-2063.
40.
PastoreCNomdedeuJVolpeG, et al. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosomes Cancer1995; 14: 106-111.
41.
SharmaAComstockCESKnudsenES, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res2007; 67: 6192-6203.
42.
MaddisonLASutherlandBWBarriosRJ, et al. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res2004; 64: 6018-6025.
43.
MelamedJEinhornJMIttmannMM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res1997; 3: 1867-1872.
44.
PhillipsSMBartonCMLeeSJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Brit J Cancer1994; 70: 1252-1257.
45.
LiCLarssonCFutrealA, et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene1998; 16: 481-487.
46.
JarrardDFModderJFaddenP, et al. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett2002; 185: 191-199.
47.
BeltranHPrandiDMosqueraJM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med2016; 22: 298-305.
48.
AparicioAMShenLTapiaELN, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res2016; 22: 1520-1530.
49.
TanH-LSoodARahimiHA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res2014; 20: 890-903.
50.
SharmaAYeowW-SErtelA, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest2010; 120: 4478-4492.
51.
KuSYRosarioSWangY, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science2017; 355: 78-83.
52.
MuPZhangZBenelliM, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science2017; 355: 84-88.
53.
MateoJSeedGBertanC, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest2020; 130: 1743-1751.
54.
KluthMScherzaiSBüschekF, et al. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes Cancer2018; 57: 504-512.
55.
AbidaWCyrtaJHellerG, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A2019; 116: 11428-11436.
56.
Nava RodriguesDCasiraghiNRomanelA, et al. RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Clin Cancer Res2019; 25: 687-697.
57.
FraserMSabelnykovaVYYamaguchiTN, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature2017; 541: 359-364.
58.
DaviesAHBeltranHZoubeidiA. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol2018; 15: 271-286.
59.
YuanSNorgardRJStangerBZ. Cellular plasticity in cancer. Cancer Discov2019; 9: 837-851.
60.
GeRWangZMontironiR, et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol2020; 31: 470-479.
61.
FormaggioNRubinMATheurillatJ-P. Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene2021; 40: 1205-1216.
62.
CaiMSongX-LLiX-A, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat2023; 68: 100962.
63.
TranCOukSCleggNJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science2009; 324: 787-790.
64.
de BonoJSLogothetisCJMolinaA, et al. Abiraterone and increased survival in metastatic prostate cancer. New Eng Journal of Medicine2011; 364: 1995-2005.
65.
ScherHIFizaziKSaadF, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England J Med2012; 367: 1187-1197.
66.
QuigleyDADangHXZhaoSG, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell2018; 175: 889.
67.
GrassoCSWuY-MRobinsonDR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature2012; 487: 239-243.
68.
NouriMMassahSCaradecJ, et al. Transient Sox9 expression facilitates resistance to androgen-targeted therapy in prostate cancer. Clin Cancer Res2020; 26: 1678-1689.
69.
KnudsenESPruittSCHershbergerPA, et al. Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy. Trends Cancer2019; 5: 308-324.
70.
IshakCAMarshallAEPassosDT, et al. An RB-EZH2 complex mediates silencing of repetitive DNA sequences. Mol Cell2016; 64: 1074-1087.
71.
BrackenAPPasiniDCapraM, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J2003; 22: 5323-5335.
72.
KaretaMSGorgesLLHafeezS, et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell2015; 16: 39-50.
73.
HanWLiuMHanD, et al. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene2022; 41: 852-864.
74.
DysonN. The regulation of E2F by pRB-family proteins. Genes Dev1998; 12: 2245-2262.
75.
TsegayPSLaiYLiuY. Replication stress and consequential instability of the genome and epigenome. Molecules2019; 24: 3870.
76.
LinderSHoogstraatMStellooS, et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence. Cancer Discov2022; 12: 2074-2097.
77.
GonzaloSGarcía-CaoMFragaMF, et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol2005; 7: 420-428.
78.
IsaacCEFrancisSMMartensAL, et al. The retinoblastoma protein regulates pericentric heterochromatin. Mol Cell Biol2006; 26: 3659-3671.
79.
SiddiquiHFoxSRGunawardenaRW, et al. Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics. J Cell Physiol2007; 211: 131-137.
80.
KorenjakMBrehmA. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev2005; 15: 520-527.
81.
RodriguesDNBoysenGSumanasuriyaS, et al. The molecular underpinnings of prostate cancer: impacts on management and pathology practice. J Pathol2017; 241: 173-182.
82.
FanLGongYHeY, et al. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. Oncogene2022; 42: 559–571.
83.
LeeARCheNLovnickiJM, et al. Development of neuroendocrine prostate cancers by the Ser/Arg repetitive matrix 4-mediated RNA splicing network. Front Oncol2018; 8: 93.
84.
BleeAMHeYYangY, et al. Controls luminal epithelial lineage and antiandrogen sensitivity in and -mutated prostate cancer. Clin Cancer Res2018; 24: 4551-4565.
85.
Ben-SalemSVenkadakrishnanVBHeemersHV. Novel insights in cell cycle dysregulation during prostate cancer progression. Endocr Relat Cancer2021; 28: R141-R155.
86.
FeitelsonMAArzumanyanAKulathinalRJ, et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol2015; 35: S25-S54.
87.
PackLRDaighLHMeyerT. Putting the brakes on the cell cycle: mechanisms of cellular growth arrest. Curr Opin Cell Biol2019; 60: 106-113.
DysonNJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev2016; 30: 1492-1502.
90.
RubinSMSageJSkotheimJM. Integrating old and new paradigms of G1/S control. Mol Cell2020; 80: 183-192.
91.
JanostiakRTorres-SanchezAPosasF, et al. Understanding retinoblastoma post-translational regulation for the design of targeted cancer therapies. Cancers (Basel)2022; 14: 1265.
92.
van den HeuvelSDysonNJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol2008; 9: 713-724.
93.
SunHWangYChinnamM, et al. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc Natl Acad Sci U S A2011; 108: 704-709.
94.
HoADowdySF. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev2002; 12: 47-52.
95.
ClassonMHarlowE. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer2002; 2: 910-917.
96.
KnudsenESKnudsenKE. Tailoring to RB: Tumour suppressor status and therapeutic response. Nat Rev Cancer2008; 8: 714-724.
97.
GiacintiCGiordanoA. RB and cell cycle progression. Oncogene2006; 25: 5220-5227.
98.
SullivanMMorganDO. Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol2007; 8: 894-903.
99.
SatyanarayanaAKaldisP. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene2009; 28: 2925-2939.
100.
MoserJMillerICarterD, et al. Control of the restriction point by Rb and p21. Proc Natl Acad Sci U S A2018; 115: E8219-E8227.
101.
Di FioreRD'AnneoATesoriereG, et al. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol2013; 228: 1676-1687.
102.
JiPJiangHRekhtmanK, et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell2004; 16: 47-58.
103.
BinnéUKClassonMKDickFA, et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol2007; 9: 225-232.
104.
TanejaSSHaSGarabedianMJ. Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression. J Cell Biochem2001; 84: 188-199.
105.
GhoshPMMalikSNBedollaRG, et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer2005; 12: 119-134.
106.
ZhangZGaoNHeH, et al. Vanadate activated Akt and promoted S phase entry. Mol Cell Biochem2004; 255: 227-237.
107.
GaoNZhangZJiangB-H, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun2003; 310: 1124-1132.
108.
BaoJ-MHeM-YLiuY-W, et al. AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res2015; 5: 1741-1750.
109.
NyquistMDCorellaAColemanI, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep2020; 31: 107669.
110.
GaoSGaoYHeHH, et al. Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein. Cell Rep2016; 17: 966-976.
111.
HanDChenSHanW, et al. ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer. Cancer Res2019; 79: 5260-5271.
112.
AkamatsuSWyattAWLinD, et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep2015; 12: 922-936.
113.
LiuHWuZZhouH, et al. The SOX4/miR-17-92/RB1 axis promotes prostate cancer progression. Neoplasia2019; 21: 765-776.
114.
ZhouYJinXMaJ, et al. HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer. Cancer Res2021; 81: 1486-1499.
115.
KnudsenKEArdenKCCaveneeWK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem1998; 273: 20213-20222.
TanXMartinSJGreenDR, et al. Degradation of retinoblastoma protein in tumor necrosis factor- and CD95-induced cell death. J Biol Chem1997; 272: 9613-9616.
125.
ChauBNBorgesHLChenT-T, et al. Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat Cell Biol2002; 4: 757-765.
126.
HanJSolettiRCSadaranganiA, et al. Nuclear expression of β-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells. Mol Cancer Res2013; 11: 207-218.
127.
HilgendorfKILeshchinerESNedelcuS, et al. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev2013; 27: 1003-1015.
128.
MandigoACShafiAAMcCannJJ, et al. Novel oncogenic transcription factor cooperation in RB-deficient cancer. Cancer Res2022; 82: 221-234.
129.
HamidAAGrayKPShawG, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol2019; 76: 89-97.
130.
KohliMTanWZhengT, et al. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMed2020; 54: 102728.
131.
ThangavelCBoopathiELiuY, et al. RB loss promotes prostate cancer metastasis. Cancer Res2017; 77: 982-995.
132.
MandelkerDZhangLKemelY, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA2017; 318: 825-835.
133.
CastroEGohCLeongamornlertD, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol2015; 68: 186-193.
134.
WarnerEHerbertsCFuS, et al. BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression. Clin Cancer Res2021; 27: 1650-1662.
135.
PritchardCCMateoJWalshMF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. New Eng J Med2016; 375: 443-453.
136.
AnnalaMStrussWJWarnerEW, et al. Treatment outcomes and tumor loss of heterozygosity in germline dna repair-deficient prostate cancer. Eur Urol2017; 72: 34-42.
137.
ChakrabortyGArmeniaJMazzuYZ, et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin Cancer Res2020; 26: 2047-2064.
138.
LozanoRCastroELopez-CamposF, et al. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. Eur J Cancer2023; 185: 105-118.
139.
QianCYangQFreedlandSJ, et al. Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer. Am J Clin Exp Urol2022; 10: 397-407.
140.
WangGLunardiAZhangJ, et al. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet2013; 45: 739-746.
141.
DesaiKMcManusJMSharifiN. Hormonal therapy for prostate cancer. Endocrine Rev2021; 42: 354-373.
142.
GuoCYehSNiuY, et al. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Cancer Lett2017; 397: 133-143.
143.
MitsiadesNKaocharS. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. Endocr Relat Cancer2021; 28: T19-T38.
144.
YamadaYBeltranH. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep2021; 23: 15.
145.
NiuYGuoCWenS, et al. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. Cancer Lett2018; 439: 47-55.
146.
ZongYGoldsteinAS. Adaptation or selection-mechanisms of castration-resistant prostate cancer. Nat Rev Urol2013; 10: 90-98.
147.
AggarwalRHuangJAlumkalJJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol2018; 36: 2492-2503.
148.
WangYWangYCiX, et al. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol2021; 18: 581-596.
149.
ChinnamMGoodrichDW. RB1, development, and cancer. Curr Top Dev Biol2011; 94: 129-169.
150.
MackPCChiSGMeyersFJ, et al. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate1998; 34: 145-151.
151.
ThangavelCBoopathiECimentS, et al. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness. Clin Cancer Res2014; 20: 5468-5482.
152.
de LeeuwRBerman-BootyLDSchiewerMJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res2015; 21: 795-807.
153.
HongHTakahashiKIchisakaT, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature2009; 460: 1132-1135.
154.
MiaoCTsujinoTTakaiT, et al. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Sci Adv2022; 8: eabl9794.
155.
SaadFClarkeNWOyaM, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol2023; 24: 1094-1108.
156.
ChiKNSandhuSSmithMR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol2023; 34: 772-782.
157.
AgarwalNAzadAACarlesJ, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet2023; 402: 291-303.
158.
RaoAMokaNHamstraDA, et al. Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now?Cancers (Basel)2022; 14: 801.
159.
LiMLiuMHanW, et al. LSD1 inhibition disrupts super-enhancer-driven oncogenic transcriptional programs in castration-resistant prostate cancer. Cancer Res2023; 83: 1684-1698.
